United Therapeutics Corporation
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From United Therapeutics Corporation
The FDA’s thumbs-down was largely expected after a negative advisory committee review and the path forward for the drug remains unclear – but the company is prioritizing other programs.
With only weeks to go in 2022, the three major pharmas each had inked between 16 and 20 deals. Meanwhile, Pfizer has been less busy with 12 deals, but those include M&A totaling $18.2bn.
Results from a Phase II trial have demonstrated the potential of GSK's first-in-class antitubercular agent to be a component of simpler treatment regimens for tuberculosis in the future.
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
- Large Molecule
- Other Names / Subsidiaries
- Lung Biotechnology PBC
- Lung Rx, Inc.
- SteadyMed Ltd.
- SteadyMed Therapeutics, Inc.
- Unither Pharmaceuticals
- Unither Virology